Frontlight ResearchEarly access
Active, not recruitingPhase 2
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Key facts
- Who runs it
- Translational Sciences, Inc.
- Where
- Augusta, Baltimore, Boston, Cleveland, Detroit, El Paso, Los Angeles, Philadelphia, Phoenix, Santa Barbara, Tucson, and Winston-Salem, United StatesSee the 13 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 64 people, planned
- Started
- 24 May 2023
- Expected to end
- Nov 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TS23
- Placebo
- Record updated
- 1 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female subjects, age >18 years
- PE involving a segmental or more proximal pulmonary artery confirmed by CTPA scan and with an onset of symptoms not more than 5 days prior to diagnosis
- Subject is hemodynamically stable with a systolic blood pressure (SBP) >90 mm Hg
- Subject has evidence of RV dysfunction as indicated by a right ventricular-to-left ventricular (RV/LV) diameter ratio > 0.9 on CTPA scan (measuring the minor axis of the right and left ventricle in the transverse plane), prior to the initiation of study drug administration
Who cannot take part
- Subjects for whom thrombolytic therapy or thrombectomy is planned; or subjects with history of administration of thrombolytic agents within the previous 4 days
- Subjects receiving ≥ 48 hours of therapeutic doses of heparin or low molecular weight heparin (LMWH) or other anticoagulant therapy immediately prior to randomization
- Subjects with contraindications to SOC therapies such as unfractionated heparin or LMWH or oral anticoagulant, or any of the excipients (including study drug excipients)
- Subjects who are considered at very high risk of bleeding:; Known coagulation disorder with history of pathologic bleeding tendencies; Subjects with prior intracranial hemorrhage, known arteriovenous malformation or aneurysm of the brain, or evidence of active bleeding; Subjects with a history of major surgery, clinically significant head trauma (in the opinion of the Principal Investigator), or stroke in the past 3 months prior to randomization; Subjects with uncontrolled hypertension defined as SBP ≥180 mm Hg and/or diastolic BP (DBP); ≥110 mm Hg at randomization; Subjects requiring concomitant dual antiplatelet therapy
- Female subjects of child bearing potential with a positive pregnancy test or who are lactating, or unwilling to use highly effective methods of contraception. Highly effective methods of birth control include combination hormonal therapy (estrogen and progresterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence
- Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days (or longer depending on the half-life of the investigational drug; should allow at least five half-life of the investigational drug) prior to randomization
- Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody
- Subjects with known history of testing positive for the human immunodeficiency virus (HIV)
- Subjects with Creatinine Clearance (CrCL) < 30 mL/min or serum creatinine ≥ 2.5 mg/dL
- Subjects with hemoglobin < 8.0 g/dL
- Subjects with a platelet count < 100,000/µL
- Subjects with acute or persistent hepatitis or diagnosed active liver disease or with elevation of liver enzymes: Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 x upper limit of normal (ULN)
- Subjects with life-expectancy < 6 months
Where in United States
- Wellstar MCG Health Medical CenterAugusta, United States
- Lifebridge HealthBaltimore, United States
- Tuft University HospitalBoston, United States
- Cleveland ClinicCleveland, United States
- Fairview HospitalCleveland, United States
- Henry Ford HospitalDetroit, United States
- Texas Tech University Health Sciences Center at El PasoEl Paso, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Temple University HospitalPhiladelphia, United States
- Banner University Medical CenterPhoenix, United States
- Cottage HospitalSanta Barbara, United States
- Banner University Medical Center - TucsonTucson, United States
- Wake Forest University/Atrium Health's Carolinas Medical CenterWinston-Salem, United States
About the trial
What the trial wants to find out
Phase II trial of TS23
The 4 groups in the trial
- PlaceboPlacebo, for comparison
Placebo + standard of care (SOC) anticoagulation
- Low dose TS23Treatment being tested
TS23 low dose + SOC anticoagulation
Treatment: TS23
- Intermediate dose TS23Treatment being tested
TS23 medium dose + SOC anticoagulation
Treatment: TS23
- Higher dose TS23Treatment being tested
TS23 highest dose + SOC anticoagulation
Treatment: TS23
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
- Publications
- Cerebral venous thrombosis: Current management, recent advances and future directions.International journal of stroke : official journal of the International Stroke Society, 2025
- Record updated
- 1 July 2026